RECRUITING

Chronic Thromboembolic Disease Registry

Talk to us

Conditions

Chronic Thromboembolic Pulmonary HypertensionChronic Thromboembolic Disease

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this patient registry is to learn about the natural history in patients with chronic thromboembolic disease (CTD) and/or chronic thromboembolic pulmonary hypertension (CTEPH). The main question\[s\] it aims to answer are: * Long-term outcome after various types of treatment, including medication, balloon pulmonary angioplasty, and pulmonary endarterectomy * Effect of treatment on patient's quality of life and exercise tolerance Participants will be followed longitudinally to assess their health outcomes and quality of life via chart review and health quality surveys.

Official Title

Chronic Thromboembolic Disease: A Prospective Registry

Quick Facts

Study Start:2023-08-01
Study Completion:2028-07-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05843500

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients referred with CTED and/or CTEPH defined as:
  2. 1. Mean pulmonary arterial pressure (mPAP) \> 20 mmHg at rest with pulmonary vascular resistance (PVR) \> 2 Wood units (WU); or if mPAP ≤ 20 mmHg or PVR ≤ 2 WU at rest, have exercise limitations from chronic thromboembolic pulmonary disease (CTEPD) without pulmonary hypertension (PH)
  3. 2. Radiologic finding of chronic thromboembolic disease, including abnormal ventilation perfusion scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram
  4. 3. Post-embolic exercise intolerance and evidence of chronic thromboembolic disease in the absence of resting pulmonary hypertension
  5. * Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH or CTEPD without PH
  6. * Age ≥ 18 years
  1. * Main cause of PH other than World Health Organization (WHO) group 4 (CTEPH)
  2. * Patient's refusal to participate in clinical research and/or receive intervention

Contacts and Locations

Study Contact

Miles Conrad, MD
CONTACT
(415) 353-1300
miles.conrad@ucsf.edu
Xiao Wu, MD
CONTACT
628-286-7340
xiao.wu@ucsf.edu

Principal Investigator

Miles Conrad, MD
PRINCIPAL_INVESTIGATOR
University of California, San Francisco

Study Locations (Sites)

University of California San Francisco
San Francisco, California, 94143
United States

Collaborators and Investigators

Sponsor: University of California, San Francisco

  • Miles Conrad, MD, PRINCIPAL_INVESTIGATOR, University of California, San Francisco

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-08-01
Study Completion Date2028-07-01

Study Record Updates

Study Start Date2023-08-01
Study Completion Date2028-07-01

Terms related to this study

Additional Relevant MeSH Terms

  • Chronic Thromboembolic Pulmonary Hypertension
  • Chronic Thromboembolic Disease